Does low TGF-β1 weaken inflammatory braking and promote sustained immune activation?

Transforming growth factor beta-1 (TGF-β1) is a critical pleiotropic cytokine that serves as a master regulator of immune homeostasis. It is fundamental for maintaining peripheral tolerance and preventing the body's immune system from attacking its own tissues.

Clinical and physiological evidence

The role of TGF-β1 as a potent "inflammatory brake" is well-documented in both human clinical data and animal models.

• Maintenance of tolerance: TGF-β1 is essential for the differentiation of naïve CD4+ T cells into Foxp3+ regulatory T cells (Tregs). These cells are the primary mediators of immune suppression, ensuring that the immune system does not overreact to self-antigens or harmless environmental triggers.
• Consequences of deficiency: Clinical evidence demonstrates that lower levels of TGF-β1 are associated with an inability to resolve inflammation, leading to sustained immune activation. In conditions such as inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD), reduced TGF-β1 correlates with higher inflammatory biomarkers and increased disease severity.
• Systemic impact: Research in knockout models shows that a complete absence or significant reduction of TGF-β1 leads to rapid, lethal multiorgan inflammatory disease. This is characterized by a "cytokine storm" of pro-inflammatory mediators like TNF-α and IFN-γ, illustrating that without this cytokine, even minor immune challenges can trigger uncontrolled, sustained inflammation.

Mechanistic explanations

TGF-β1 limits inflammation through several sophisticated molecular pathways:

• NF-κB inhibition: TGF-β1 activates GSK-3β, which stabilizes β-catenin. This protein physically binds to the p65 subunit of NF-κB, a central driver of the inflammatory response, preventing it from entering the nucleus and activating genes for pro-inflammatory cytokines like TNF-α and IL-1.
• Direct lymphocyte suppression: It signals through a heteromeric receptor complex (TβRI/TβRII) to activate Smad2 and Smad3. This pathway regulates the transcription of genes that induce cell cycle arrest in activated T cells and natural killer (NK) cells, effectively curbing their proliferation and effector functions.
• Apoptosis induction: To resolve an active immune response, TGF-β1 can induce programmed cell death (apoptosis) in activated lymphocytes, ensuring the inflammatory response does not persist beyond its physiological necessity.

Bottom line

TGF-β1 is a cornerstone of immune regulation; its presence is required to sustain "inflammatory braking" and immune tolerance. Lower levels of this cytokine weaken these regulatory checkpoints, significantly lowering the threshold for sustained, chronic immune activation and increasing the risk of systemic inflammation.